COST EFFECTIVENESS OF DIFFERENT TARGETED TREATMENT SEQUENCES FOR HER2-POSITIVE METASTATIC BREAST CANCER

被引：0
|
作者：
Diaby, V [1 ]
Adunlin, G. [2 ]
Ali, A. [1 ]
Zeichner, S. [3 ]
Lopes, G. [4 ]
Kohn, C. G. [5 ]
Montero, A. J. [6 ]
机构：
[1] Florida A&M Univ, Tallahassee, FL 32307 USA
[2] Virginia Commonwealth Univ, Richmond, VA USA
[3] Emory Univ, Atlanta, GA 30322 USA
[4] Hosp Coracao & Oncoclin Brasil Grp, Sao Paulo, Brazil
[5] Univ St Joseph, Hartford Hosp, Evidence Based Practice Ctr, Hartford, CT USA
[6] Cleveland Clin, Cleveland, OH 44106 USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1592
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN93
引用
收藏
页码：A150 / A150
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
    Garrison, Louis R., Jr.
    Lubeck, Deborah
    Lalla, Deepa
    Paton, Virginia
    Dueck, Amylou
    Perez, Edith A.
    CANCER, 2007, 110 (03) : 489 - 498
  • [32] Cost-effectiveness of different neoadjuvant followed by adjuvant treatment combination strategies for women with HER2-positive breast cancer
    Kunst, Natalia R.
    Wang, Shi-Yi
    Hood, Annette
    Mougalian, Sarah
    DiGiovanna, Michael P.
    Adelson, Kerin
    Pusztai, Lajos
    CANCER RESEARCH, 2020, 80 (04)
  • [33] Systemic treatment of HER2-positive metastatic breast cancer: A systematic review
    Wilcken, Nicholas
    Zdenkowski, Nicholas
    White, Michelle
    Snyder, Ray
    Pittman, Ken
    Mainwaring, Paul
    Green, Michael
    Francis, Prudence
    De Boer, Richard
    Colosimo, Maree
    Chua, Sue
    Chirgwin, Jacquie
    Beith, Jane
    Bell, Richard
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 1 - 14
  • [34] Treatment of HER2-Positive Metastatic Breast Cancer Following Initial Progression
    Mayer, Ingrid A.
    CLINICAL BREAST CANCER, 2009, 9 : S50 - S57
  • [35] Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
    Paridaens, R., Sr.
    Wildiers, H.
    Dalenc, F.
    Rixe, O.
    Cadic, V.
    Pinel, M.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe
    Piccart, MJ
    ANNALS OF ONCOLOGY, 2001, 12 : 89 - 94
  • [37] Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore
    Cheng, Li-Jen
    Loke, Lydia
    Lim, Elaine Hsuen
    Pearce, Fiona
    Aziz, Mohamed Ismail Abdul
    Ng, Kwong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 449 - 456
  • [38] Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer
    Montagna, Emilia
    Colleoni, Marco
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [39] Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
    Hong, Joohyun
    Park, Yeon Hee
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [40] Targeted therapy in HER2-positive breast cancer (Review)
    Li, Shu Guang
    Li, Li
    BIOMEDICAL REPORTS, 2013, 1 (04) : 499 - 505
12345